Video
Author(s):
Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.
Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events (AEs).
An area of prostate cancer that Bradley says needs more research is in terms of AE management for prostate cancer survivors. A lot of patients become very fatigued while undergoing therapy, and getting them up and exercising is an important way to overcome this. It is widely known that a common AE associated with chemotherapy is fatigue, but more work needs to be geared toward this. Bradley stressed that as therapy becomes more advanced, patient quality of life is a necessary important endpoint in clinical trials.
Additionally, as these therapies are moved into earlier settings, cardiac toxicity could become a factor. If a patient’s testosterone is being suppressed for such an extended period of time, researchers have to better understand the long-term AEs that could occur. Proper exercise regimens could be crucial here, as well.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
2 Commerce Drive
Cranbury, NJ 08512